2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206

Data ReadoutpositiveIASO206Positive

AI Analysis

Summary

IASO Bio presented first-in-human data for IASO206, a BCMA-targeted in vivo CAR-T cell therapy, showing 90% objective response rate and 90% MRD negativity with a single IV infusion without lymphodepleting chemotherapy. The positive early-stage results were presented as a late-breaking abstract at IMS 2026.

Clinical Trial Data

Phase

Phase_1

Primary Endpoint

Met

Outcome Details

90% objective response rate and 90% MRD negativity rate in first-in-human study of IASO206, a single-dose in vivo CAR-T cell therapy without lymphodepleting chemotherapy

Importance:7/10

Sentiment:

0.85

CAR-T therapyBCMA targetingfirst-in-humanin vivooncologylate-breaking abstractIMS 2026 conference

Related Companies

$MEHA $TRAX

Read the original article

Published by PR Newswire Biotech on September 27, 2026 3:03 AM

Read Original